Nautilus Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
NAUT$2.38+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Nautilus Biotechnology, Inc.Consolidated Balance SheetsAt December 31, 2025 and 2024
| (in thousands, except share and per share amounts) | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $12,388 | $27,646 |
| Short-term investments | 91,018 | 102,247 |
| Prepaid expenses and other current assets | 2,557 | 2,933 |
| Total current assets | 105,963 | 132,826 |
| Property and equipment, net | 3,457 | 4,076 |
| Operating lease right-of-use assets | 27,773 | 28,256 |
| Long-term investments | 52,739 | 76,405 |
| Other long-term assets | 1,180 | 1,180 |
| Total assets | $191,112 | $242,743 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $943 | $987 |
| Accrued expenses and other liabilities | 3,177 | 2,548 |
| Current portion of operating lease liability | 3,832 | 4,097 |
| Total current liabilities | 7,952 | 7,632 |
| Operating lease liability, net of current portion | 26,187 | 26,381 |
| Total liabilities | 34,139 | 34,013 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 200,000,000 authorized as of December 31, 2025 and 2024, respectively; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — |
| Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 126,469,610 and 126,106,176 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 13 | 13 |
| Additional paid-in capital | 488,737 | 481,679 |
| Accumulated other comprehensive income | 243 | 57 |
| Accumulated deficit | (332,020) | (273,019) |
| Total stockholders’ equity | 156,973 | 208,730 |
| Total liabilities and stockholders’ equity | $191,112 | $242,743 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.